These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21478328)

  • 81. Using an interim analysis based exclusively on an early outcome in a randomized clinical trial with a long-term clinical endpoint.
    Garcia Barrado L; Burzykowski T; Legrand C; Buyse M
    Pharm Stat; 2022 Jan; 21(1):209-219. PubMed ID: 34505395
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Group sequential two-stage preference designs.
    Liu R; Li F; Esserman D; Ryan MM
    Stat Med; 2024 Jan; 43(2):315-341. PubMed ID: 38010193
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Maximum inflation of the type 1 error rate when sample size and allocation rate are adapted in a pre-planned interim look.
    Graf AC; Bauer P
    Stat Med; 2011 Jun; 30(14):1637-47. PubMed ID: 21495058
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A Two-Stage Decision Making Approach for Safety Studies.
    Kim J; Huang Z
    J Biopharm Stat; 2021 Nov; 31(6):828-837. PubMed ID: 34775915
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Accuracy in parameter estimation for a general class of effect sizes: A sequential approach.
    Kelley K; Darku FB; Chattopadhyay B
    Psychol Methods; 2018 Jun; 23(2):226-243. PubMed ID: 28383948
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Interim analysis for binary outcome trials with a long fixed follow-up time and repeated outcome assessments at pre-specified times.
    Parpia S; Julian JA; Gu C; Thabane L; Levine MN
    Springerplus; 2014; 3():323. PubMed ID: 25019050
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Estimation of conditional power in the presence of auxiliary data.
    Li X; Yung G; Lin J; Zhu J
    Stat Med; 2023 Oct; 42(24):4319-4332. PubMed ID: 37493067
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Combining an Internal Pilot with an Interim Analysis for Single Degree of Freedom Tests.
    Kairalla JA; Muller KE; Coffey CS
    Commun Stat Theory Methods; 2010 Dec; 39(20):3717-3738. PubMed ID: 21037942
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Information-based group sequential design for post-market safety monitoring of medical products using real world data.
    Zhang Z; Nielson C; Chuo CY; Ye Z
    Pharm Stat; 2024; 23(5):778-790. PubMed ID: 38586914
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Information fraction estimation based on the number of events within the standard treatment regimen.
    Dang HM; Alonzo T; Franklin M; Mack WJ; Krailo MD; Eckel SP
    Biom J; 2020 Dec; 62(8):1960-1972. PubMed ID: 32627859
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials.
    Gao P; Li Y
    J Biopharm Stat; 2024 May; 34(3):424-440. PubMed ID: 37526434
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A Bayesian Sequential Design for Clinical Trials with Time-to-Event Outcomes.
    Zhu L; Yu Q; Mercante DE
    Stat Biopharm Res; 2019; 11(4):387-397. PubMed ID: 32226580
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Group-sequential analysis may allow for early trial termination: illustration by an intra-observer repeatability study.
    Gerke O; Vilstrup MH; Halekoh U; Hildebrandt MG; Høilund-Carlsen PF
    EJNMMI Res; 2017 Sep; 7(1):79. PubMed ID: 28952076
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Dynamic incorporation of real world evidence within the framework of adaptive design.
    Lin J; Liao R; Gamalo-Siebers M
    J Biopharm Stat; 2022 Nov; 32(6):986-998. PubMed ID: 35730907
    [TBL] [Abstract][Full Text] [Related]  

  • 95. An evaluation of increasing sample size based on conditional power.
    Gaffney M; Ware JH
    J Biopharm Stat; 2017; 27(5):797-808. PubMed ID: 28166460
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Using an early outcome as the sole source of information of interim decisions regarding treatment effect on a long-term endpoint: The non-Gaussian case.
    Garcia Barrado L; Burzykowski T
    Pharm Stat; 2024 Jun; ():. PubMed ID: 38837876
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Design considerations for case series models with exposure onset measurement error.
    Mohammed SM; Dalrymple LS; Sentürk D; Nguyen DV
    Stat Med; 2013 Feb; 32(5):772-86. PubMed ID: 22911898
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A systematic review of the "promising zone" design.
    Edwards JM; Walters SJ; Kunz C; Julious SA
    Trials; 2020 Dec; 21(1):1000. PubMed ID: 33276810
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Estimating the standardized mean difference with minimum risk: Maximizing accuracy and minimizing cost with sequential estimation.
    Chattopadhyay B; Kelley K
    Psychol Methods; 2017 Mar; 22(1):94-113. PubMed ID: 27607545
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Properties of Estimators in Exponential Family Settings with Observation-based Stopping Rules.
    Milanzi E; Molenberghs G; Alonso A; Kenward MG; Verbeke G; Tsiatis AA; Davidian M
    J Biom Biostat; 2016 Feb; 7(1):. PubMed ID: 27175309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.